UPDATE: UBS Investment Research Raises PT on Mylan Following Investor Day

In a report published Friday, UBS Investment Research analyst Marc Goodman reiterated a Buy rating on Mylan (NASDAQ: MYL), and raised the price target from $36.00 to $39.00. In the report, UBS Investment Research noted, “Mgt did a good job detailing key drivers (injectables, respiratory, ARV, biologics, Copaxone, strong pipeline, geographical